Epigenetic regulation of cardiac electrophysiology in atrial fibrillation: HDAC2 determines action potential duration and suppresses NRSF in cardiomyocytes
Patrick Lugenbiel(Heidelberg University), Dierk Thomas(Heidelberg University), Daniel Finke(Heidelberg University), Emili Manolova(Heidelberg University), Norbert Frey(University Hospital Schleswig-Holstein), Steffi Sandke(Heidelberg University), Ann‐Kathrin Rahm(Heidelberg University), Nadine Weiberg(Heidelberg University), Dominik Gramlich(Heidelberg University), Lorenz Lehmann(German Cancer Research Center), Rasmus Rivinius(Heidelberg University), Arjang Ruhparwar(Essen University Hospital), Patrick Most(Thomas Jefferson University), Katharina Govorov(Heidelberg University), Pascal Syren(Heidelberg University), Maximilian N. Wunsch(German Centre for Cardiovascular Research), Hugo A. Katus(Heidelberg University), Tanja Weis(Heidelberg University), Teresa Wieder(Heidelberg University), Bastian Schmack(Heidelberg University), Tanja Heimberger(Comprehensive Cancer Center Mainfranken), Patrick A. Schweizer(Goethe University Frankfurt), Claus Bruehl(Heinrich Heine University Düsseldorf), Fadwa A. El Tahry(Heidelberg University), Matthias Karck(Heidelberg University), Derk Frank(Schmerzklinik Kiel)
Cited by 17
Related Papers
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease
|European Heart Journal|2020|1.8k
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2020|1.2k
European Society of Cardiology: cardiovascular disease statistics 2021
|European Heart Journal|2021|1.1k
Myocardial infarction accelerates atherosclerosis
|Nature|2012|1.1k